Positive News SentimentPositive NewsNASDAQ:PRVB Provention Bio (PRVB) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free PRVB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$24.98▼$25.0050-Day Range$23.74▼$24.9852-Week Range$3.18▼$25.00Volume9.12 million shsAverage Volume2.28 million shsMarket Capitalization$2.37 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Provention Bio alerts: Email Address Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Provention Bio Stock (NASDAQ:PRVB)Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Read More Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… PRVB Stock News HeadlinesDecember 29, 2023 | morningstar.comMacrogenics Inc MGNXMay 1, 2023 | finance.yahoo.comSanofi/Provention: innovative diabetes drug is a good fitMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!April 29, 2023 | finance.yahoo.comThose who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%April 28, 2023 | seekingalpha.comSanofi completes Provention Bio acquisitionApril 27, 2023 | finance.yahoo.comEarnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to DeclineApril 27, 2023 | finanznachrichten.deSanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 26, 2023 | seekingalpha.comProvention Bio gains after HSR waiting period for Sanofi deal expiredMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!April 26, 2023 | benzinga.comPress Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 22, 2023 | finance.yahoo.comPRVB Apr 2023 23.000 putApril 11, 2023 | msn.comSanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More InformationApril 2, 2023 | finance.yahoo.comProvention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 27, 2023 | bizjournals.comGaithersburg’s Novavax locks in consulting deal with outgoing R&D headMarch 17, 2023 | benzinga.com(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?March 16, 2023 | finance.yahoo.comQ4 2022 MacroGenics Inc Earnings CallMarch 15, 2023 | benzinga.comProvention Bio's Earnings OutlookMarch 14, 2023 | msn.comSMBC Nikko Downgrades Provention Bio (PRVB)March 14, 2023 | msn.comJefferies Downgrades Provention Bio (PRVB)March 14, 2023 | proactiveinvestors.comProvention Bio shares soar after Sanofi agrees to buy company in $2.9B cash dealMarch 14, 2023 | benzinga.comShort Volatility Alert: Provention Bio IncMarch 14, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Provention BioMarch 13, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with SanofiMarch 13, 2023 | finance.yahoo.comProvention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference CallMarch 13, 2023 | msn.comSanofi agrees to $2.9B purchase of Provention Bio in bid to boost diabetes drugMarch 13, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Provention Bio, Inc. BuyoutMarch 13, 2023 | businesswire.comPRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to ShareholdersSee More Headlines Receive PRVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRVB CUSIPN/A CIK1695357 Webwww.proventionbio.com Phone(908) 428-9136FaxN/AEmployees82Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,570,000.00 Net Margins-880.69% Pretax Margin-984.54% Return on Equity-103.36% Return on Assets-69.08% Debt Debt-to-Equity Ratio0.19 Current Ratio1.93 Quick Ratio1.92 Sales & Book Value Annual Sales$12.90 million Price / Sales183.54 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book17.84Miscellaneous Outstanding Shares94,780,000Free Float82,365,000Market Cap$2.37 billion OptionableNot Optionable Beta2.47 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesAshleigh W. PalmerChief Executive Officer & DirectorChristina YiChief Operating OfficerThierry ChaucheChief Financial OfficerFrancisco LeonChief Scientific OfficerEleanor Leni RamosChief Medical OfficerKey CompetitorsRhythm PharmaceuticalsNASDAQ:RYTMKeros TherapeuticsNASDAQ:KROSTG TherapeuticsNASDAQ:TGTXRocket PharmaceuticalsNASDAQ:RCKTAlpine Immune SciencesNASDAQ:ALPNView All CompetitorsInsidersSessa Capital (Master), L.P.Sold 2,190,549 sharesTotal: $53.27 M ($24.32/share) PRVB Stock Analysis - Frequently Asked Questions How were Provention Bio's earnings last quarter? Provention Bio, Inc. (NASDAQ:PRVB) released its earnings results on Thursday, November, 4th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.08. The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $3.75 million. Provention Bio had a negative trailing twelve-month return on equity of 103.36% and a negative net margin of 880.69%. During the same period last year, the business earned ($0.56) earnings per share. What other stocks do shareholders of Provention Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV). This page (NASDAQ:PRVB) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provention Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.